In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia - PubMed (original) (raw)
. 1997 Oct 1;90(7):2723-9.
Affiliations
- PMID: 9326239
Free article
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia
G J Kaspers et al. Blood. 1997.
Free article
Abstract
As an important determinant of the response to chemotherapy, measurements of cellular drug resistance may provide prognostically significant information, which could be useful for optimal risk-group stratification. The objective of this report is to determine the relation between in vitro resistance to 12 drugs, measured with the colorimetric methyl-thiazol-tetrazolium (MTT) assay, and long-term clinical response to chemotherapy in 152 children with newly diagnosed acute lymphoblastic leukemia. At risk-group stratified analyses, in vitro resistance to prednisolone, L-asparaginase, and vincristine were each significantly (P < .01) related to the probability of disease-free survival (pDFS) after combination chemotherapy. The combination of data for prednisolone, L-asparaginase, and vincristine provided a drug-resistance profile with prognostic independent significance superior to that of any single drug or any other factor. The 3-years pDFS was 100% for the group with the most sensitive profile, 20% of all patients, 84% (SE 6%) for the group with an intermediately sensitive profile, 40% of all patients, and 43% (SE 8%) for the remaining group with the most resistant profile (P < .001). In conclusion, the extent of in vitro cellular resistance to prednisolone, L-asparaginase, and vincristine, measured using the MTT assay, was significantly related to the clinical response to combination chemotherapy. Treatment failure in newly diagnosed childhood ALL can be predicted based on cellular drug resistance data.
Similar articles
- In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. Hongo T, et al. Blood. 1997 Apr 15;89(8):2959-65. Blood. 1997. PMID: 9108416 - Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T, Yamada S, Yajima S, Watanabe C, Fujii Y, Kawasaki H, Yazaki M, Hanada R, Horikoshi Y. Hongo T, et al. Int J Hematol. 1999 Dec;70(4):268-77. Int J Hematol. 1999. PMID: 10643153 - Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ, Janka-Schaub GE. Den Boer ML, et al. J Clin Oncol. 2003 Sep 1;21(17):3262-8. doi: 10.1200/JCO.2003.11.031. J Clin Oncol. 2003. PMID: 12947061 - Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M, Burke GA, Lowis SP, Estlin EJ. Ronghe M, et al. Cancer Treat Rev. 2001 Dec;27(6):327-37. doi: 10.1053/ctrv.2001.0243. Cancer Treat Rev. 2001. PMID: 11908926 Review. - Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, Botsonis A, Tsangaris GT. Tzortzatou-Stathopoulou F, et al. J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
Cited by
- Prognostic Relevance of Expression of EMP1, CASP1, and NLRP3 Genes in Pediatric B-Lineage Acute Lymphoblastic Leukemia.
Singh J, Kumari S, Arora M, Verma D, Palanichamy JK, Kumar R, Sharma G, Bakhshi S, Pushpam D, Ali MS, Ranjan A, Tanwar P, Chauhan SS, Singh A, Chopra A. Singh J, et al. Front Oncol. 2021 Mar 5;11:606370. doi: 10.3389/fonc.2021.606370. eCollection 2021. Front Oncol. 2021. PMID: 33747919 Free PMC article. - Therapeutic trials in childhood ALL: what's their future?
Eden OB. Eden OB. J Clin Pathol. 2000 Jan;53(1):55-9. doi: 10.1136/jcp.53.1.55. J Clin Pathol. 2000. PMID: 10767858 Free PMC article. Review. No abstract available. - Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL.
Watanabe A, Miyake K, Yamada Y, Sunamura EI, Yotani T, Kagami K, Kasai S, Tamai M, Harama D, Akahane K, Goi K, Sakaguchi K, Goto H, Kitahara S, Inukai T. Watanabe A, et al. Epigenetics. 2023 Dec;18(1):2268814. doi: 10.1080/15592294.2023.2268814. Epub 2023 Oct 15. Epigenetics. 2023. PMID: 37839090 Free PMC article. - Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells.
He Y, Li B, Luo C, Shen S, Chen J, Xue H, Tang J, Gu L. He Y, et al. J Huazhong Univ Sci Technolog Med Sci. 2011 Apr;31(2):159-163. doi: 10.1007/s11596-011-0243-4. Epub 2011 Apr 20. J Huazhong Univ Sci Technolog Med Sci. 2011. PMID: 21505976 - c-Myb interacts with the glucocorticoid receptor and regulates its level in pre-B-acute lymphoblastic leukemia cells.
Sarvaiya PJ, Schwartz JR, Geng CD, Vedeckis WV. Sarvaiya PJ, et al. Mol Cell Endocrinol. 2012 Sep 25;361(1-2):124-32. doi: 10.1016/j.mce.2012.03.024. Epub 2012 Apr 10. Mol Cell Endocrinol. 2012. PMID: 22516378 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials